Cargando…

The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study

BACKGROUND: Although both type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are associated with increased risk of cardiovascular disease (CVD), evidence is lacking as to whether the presence of NAFLD confers an additional risk of CVD in patients with T2DM. We investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jiyun, Kim, Gyuri, Kim, Bong-Sung, Han, Kyung-Do, Kwon, So Yoon, Park, So Hee, Lee, You-Bin, Jin, Sang-Man, Kim, Jae Hyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013458/
https://www.ncbi.nlm.nih.gov/pubmed/35429980
http://dx.doi.org/10.1186/s12933-022-01483-y
_version_ 1784687999415484416
author Park, Jiyun
Kim, Gyuri
Kim, Bong-Sung
Han, Kyung-Do
Kwon, So Yoon
Park, So Hee
Lee, You-Bin
Jin, Sang-Man
Kim, Jae Hyeon
author_facet Park, Jiyun
Kim, Gyuri
Kim, Bong-Sung
Han, Kyung-Do
Kwon, So Yoon
Park, So Hee
Lee, You-Bin
Jin, Sang-Man
Kim, Jae Hyeon
author_sort Park, Jiyun
collection PubMed
description BACKGROUND: Although both type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are associated with increased risk of cardiovascular disease (CVD), evidence is lacking as to whether the presence of NAFLD confers an additional risk of CVD in patients with T2DM. We investigated the associations between hepatic steatosis and/or fibrosis and risk of myocardial infarction (MI), stroke, heart failure (HF), and mortality in patients with new-onset T2DM. METHODS: Using the Korean National Health Insurance dataset, we included 139,633 patients diagnosed with new-onset T2DM who underwent a national health screening from January 2009 to December 2012. Hepatic steatosis and advanced hepatic fibrosis were determined using cutoff values for fatty liver index (FLI) and BARD score. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards regression models. RESULTS: During the median follow-up of 7.7 years, there were 3,079 (2.2%) cases of MI, 4,238 (3.0%) cases of ischemic stroke, 4,303 (3.1%) cases of HF, and 8,465 (6.1%) all-cause deaths. Hepatic steatosis defined as FLI ≥ 60 was associated with increased risk for MI (HR [95% CI], 1.28 [1.14–1.44]), stroke (1.41 [1.25–1.56]), HF (1.17 [1.07–1.26]), and mortality (1.41 [1.32–1.51]) after adjusting for well-known risk factors. Compared to the group without steatosis, the group with steatosis and without fibrosis (BARD < 2) and the group with both steatosis and fibrosis (BARD ≥ 2) showed gradual increased risk for MI, stroke, HF, and mortality (all p for trends < 0.001). CONCLUSION: Hepatic steatosis and/or advanced fibrosis as assessed by FLI or BARD score were significantly associated with risk of CVD and mortality in new-onset T2DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01483-y.
format Online
Article
Text
id pubmed-9013458
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90134582022-04-18 The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study Park, Jiyun Kim, Gyuri Kim, Bong-Sung Han, Kyung-Do Kwon, So Yoon Park, So Hee Lee, You-Bin Jin, Sang-Man Kim, Jae Hyeon Cardiovasc Diabetol Research BACKGROUND: Although both type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are associated with increased risk of cardiovascular disease (CVD), evidence is lacking as to whether the presence of NAFLD confers an additional risk of CVD in patients with T2DM. We investigated the associations between hepatic steatosis and/or fibrosis and risk of myocardial infarction (MI), stroke, heart failure (HF), and mortality in patients with new-onset T2DM. METHODS: Using the Korean National Health Insurance dataset, we included 139,633 patients diagnosed with new-onset T2DM who underwent a national health screening from January 2009 to December 2012. Hepatic steatosis and advanced hepatic fibrosis were determined using cutoff values for fatty liver index (FLI) and BARD score. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards regression models. RESULTS: During the median follow-up of 7.7 years, there were 3,079 (2.2%) cases of MI, 4,238 (3.0%) cases of ischemic stroke, 4,303 (3.1%) cases of HF, and 8,465 (6.1%) all-cause deaths. Hepatic steatosis defined as FLI ≥ 60 was associated with increased risk for MI (HR [95% CI], 1.28 [1.14–1.44]), stroke (1.41 [1.25–1.56]), HF (1.17 [1.07–1.26]), and mortality (1.41 [1.32–1.51]) after adjusting for well-known risk factors. Compared to the group without steatosis, the group with steatosis and without fibrosis (BARD < 2) and the group with both steatosis and fibrosis (BARD ≥ 2) showed gradual increased risk for MI, stroke, HF, and mortality (all p for trends < 0.001). CONCLUSION: Hepatic steatosis and/or advanced fibrosis as assessed by FLI or BARD score were significantly associated with risk of CVD and mortality in new-onset T2DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01483-y. BioMed Central 2022-04-16 /pmc/articles/PMC9013458/ /pubmed/35429980 http://dx.doi.org/10.1186/s12933-022-01483-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Park, Jiyun
Kim, Gyuri
Kim, Bong-Sung
Han, Kyung-Do
Kwon, So Yoon
Park, So Hee
Lee, You-Bin
Jin, Sang-Man
Kim, Jae Hyeon
The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
title The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
title_full The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
title_fullStr The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
title_full_unstemmed The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
title_short The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
title_sort associations of hepatic steatosis and fibrosis using fatty liver index and bard score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013458/
https://www.ncbi.nlm.nih.gov/pubmed/35429980
http://dx.doi.org/10.1186/s12933-022-01483-y
work_keys_str_mv AT parkjiyun theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT kimgyuri theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT kimbongsung theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT hankyungdo theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT kwonsoyoon theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT parksohee theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT leeyoubin theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT jinsangman theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT kimjaehyeon theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT parkjiyun associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT kimgyuri associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT kimbongsung associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT hankyungdo associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT kwonsoyoon associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT parksohee associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT leeyoubin associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT jinsangman associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy
AT kimjaehyeon associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy